Codiak Biosciences Inc (CDAKQ)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Douglas E. Williams
Employees:
100
C/O ARCH VENTURE PARTNERS, 999 THIRD AVENUE, SUITE 3400, SEATTLE, WA 98104
857-400-4222

Codiak BioSciences focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology and neurology. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutic S.A. and Washington University.

Data derived from most recent annual or quarterly report
Market Cap 2.099 Million Shares Outstanding36.83 Million Avg 30-day Volume 3.881 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.77
Price to Revenue0.5775 Debt to Equity0.66 EBITDA-10.66 Million
Price to Book Value0.5054 Operating Margin-156.4635 Enterprise Value-6.394 Million
Current Ratio4.236 EPS Growth-1.071 Quick Ratio3.581
1 Yr BETA 1.3548 52-week High/Low 6.98 / 0.05 Profit Margin-51.1301
Operating Cash Flow Growth22.4437 Altman Z-Score-3.3161 Free Cash Flow to Firm -89.192 Million
View SEC Filings from CDAKQ instead.

View recent insider trading info

Codiak Biosciences Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding CDAKQ (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CDAKQ

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-30 by HOWZE YALONDA
  • 4: filed on 2023-03-30 by SATHYANARAYANAN SRIRAM
  • 4: filed on 2023-03-30 by KONSTANTINOV KONSTANTIN
  • 4: filed on 2023-03-30 by BAIN LINDA
  • 4: filed on 2023-03-30 by BARNA NICOLE
  • 4: filed on 2023-03-30 by WILLIAMS DOUGLAS E
  • 4: filed on 2023-02-21 by BAIN LINDA
  • 4: filed on 2023-02-21 by WILLIAMS DOUGLAS E
  • 4: filed on 2023-02-21 by KONSTANTINOV KONSTANTIN
  • 4: filed on 2023-02-21 by BERNSTEIN KAREN

    • Events (8k)

  • 8-K: filed on 2023-03-29:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2023-03-27:
    Item 1.03: Bankruptcy or Receivership
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-14:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-30:
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-30:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-29:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-21:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-03-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-30:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    HOWZE YALONDA SEE REMARKS

    • Officer
    		 7,458 2023-03-30 5

    BARNA NICOLE SEE REMARKS

    • Officer
    		 4,849 2023-03-29 5

    SATHYANARAYANAN SRIRAM CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2023-03-29 5

    WILLIAMS DOUGLAS E PRESIDENT & CEO

    • Officer
    • Director
    		 7,655 2023-03-28 4

    BAIN LINDA CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-03-28 5

    KONSTANTINOV KONSTANTIN CHIEF TECHNOLOGY OFFICER

    • Officer
    		 0 2023-03-28 5

    COONEY CHARLES L

    • Director
    		 8,750 2023-02-16 2

    MELAS KYRIAZI THEO

    • Director
    		 15,350 2023-02-16 2

    GILLIS STEVEN

    • Director
    		 8,750 2023-02-16 3

    BERNSTEIN KAREN

    • Director
    		 8,750 2023-02-16 2

    HADDOCK JASON

    • Director
    		 8,750 2023-02-16 2

    MAURO DAVID J CHIEF MEDICAL OFFICER

    • Officer
    		 190,000 2023-01-24 2

    FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC

    FLAGSHIP VENTURES FUND V, L.P.

    FLAGSHIP V VENTURELABS RX FUND, L.P.

    AFEYAN NOUBAR

    • 10% Owner
    		 3,540,636 2022-09-15 1

    ARCH VENTURE FUND VIII, L.P.

    ARCH VENTURE FUND VIII OVERAGE, L.P.

    CRANDELL KEITH

    BYBEE CLINTON

    NELSEN ROBERT

    ARCH VENTURE PARTNERS VIII, LLC

    ARCH VENTURE PARTNERS VIII, L.P.

    • 10% Owner
    		 8,854,098 2022-09-13 1

    PANDITE ARUNDATHY N.

    • Director
    		 9,000 2022-06-17 1

    EGGIMANN ANNE-VIRGINIE

    • Director
    		 9,000 2022-06-17 1

    BRUDNICK RICHARD SEE REMARKS

    • Officer
    		 27,125 2022-02-16 0

    SORENSEN BENNY SEE REMARKS

    • Officer
    		 87,411 2021-06-08 0

    WHELER JENNIFER J. CHIEF MEDICAL OFFICER

    • Officer
    		 100,000 2021-05-10 0

    MORRISON BRIGGS

    • Director
    		 4,761 2021-02-17 0

    VERMA AJAY SEE REMARKS

    • Officer
    		 0 2021-01-22 0

    ALASKA PERMANENT FUND CORP

    • 10% Owner
    		 27,077,370 2020-10-16 0

    LANDER ERIC S

    • Director
    		 738,134 2020-10-13 0

    FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC

    FLAGSHIP VENTURELABS V LLC

    FLAGSHIP VENTURELABS V MANAGER LLC

    FLAGSHIP PIONEERING INC.

    FLAGSHIP VENTURES FUND V, L.P.

    FLAGSHIP V VENTURELABS RX FUND, L.P.

    AFEYAN NOUBAR

    • 10% Owner
    		 485,949 2020-10-13 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 22:15:04 UTC -26.9226 31.9826 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 21:45:04 UTC -26.9226 31.9826 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 21:15:03 UTC -26.9226 31.9826 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 20:45:04 UTC -26.9226 31.9826 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 20:15:06 UTC -26.9226 31.9826 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 19:45:04 UTC -26.9226 31.9826 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 19:15:21 UTC -26.9226 31.9826 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 18:45:03 UTC -26.9226 31.9826 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 18:15:04 UTC -26.9226 31.9826 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 17:45:03 UTC -26.9226 31.9826 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 17:15:05 UTC -26.9226 31.9826 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 16:45:04 UTC -26.9255 31.9955 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 16:15:04 UTC -26.9255 31.9955 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 15:45:03 UTC -26.9255 31.9955 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 15:15:04 UTC -26.9255 31.9955 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 14:45:04 UTC -26.9255 31.9955 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 14:15:03 UTC -26.9255 31.9955 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 13:45:04 UTC -26.9255 31.9955 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 13:15:04 UTC -26.9255 31.9955 1100000
    CODIAK BIOSCIENCES INC CDAKQ 2023-05-31 12:45:04 UTC -26.9255 31.9955 1100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments